These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Analysis of the secondary structure of hirudin and the mechanism of its interaction with thrombin. Konno S; Fenton JW; Villanueva GB Arch Biochem Biophys; 1988 Nov; 267(1):158-66. PubMed ID: 3196024 [TBL] [Abstract][Full Text] [Related]
5. Structure study of recombinant RGD-hirudin by vibrational and circular dichroism spectroscopy. Liu X; Mo W; Dai L; Yan X; Song H Protein Pept Lett; 2006; 13(1):47-51. PubMed ID: 16454669 [TBL] [Abstract][Full Text] [Related]
6. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group). Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527 [TBL] [Abstract][Full Text] [Related]
7. State of aggregation of recombinant hirudin in solution under physiological conditions. Thannhauser TW; Scheraga HA J Protein Chem; 1996 Nov; 15(8):751-3. PubMed ID: 9008299 [TBL] [Abstract][Full Text] [Related]
8. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Kaiser B; Simon A; Markwardt F Thromb Haemost; 1990 Feb; 63(1):44-7. PubMed ID: 2140204 [TBL] [Abstract][Full Text] [Related]
9. The characterisation of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Peters RF; Lees CM; Mitchell KA; Tweed MF; Talbot MD; Wallis RB Thromb Haemost; 1991 Mar; 65(3):268-74. PubMed ID: 1710836 [TBL] [Abstract][Full Text] [Related]
10. Detailed physicochemical characterization of the 2S storage protein from rape (Brassica napus L.). Schmidt I; Renard D; Rondeau D; Richomme P; Popineau Y; Axelos MA J Agric Food Chem; 2004 Sep; 52(19):5995-6001. PubMed ID: 15366854 [TBL] [Abstract][Full Text] [Related]
11. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657 [TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor p16INK4A: structural characterization of wild-type and mutant proteins by NMR and circular dichroism. Tevelev A; Byeon IJ; Selby T; Ericson K; Kim HJ; Kraynov V; Tsai MD Biochemistry; 1996 Jul; 35(29):9475-87. PubMed ID: 8755727 [TBL] [Abstract][Full Text] [Related]
13. The NMR solution structure of recombinant RGD-hirudin. Song X; Mo W; Liu X; Zhu L; Yan X; Song H; Dai L Biochem Biophys Res Commun; 2007 Aug; 360(1):103-8. PubMed ID: 17585879 [TBL] [Abstract][Full Text] [Related]
14. 1H NMR assignment and secondary structure of recombinant RGD-hirudin. Liu X; Yan X; Mo W; Song H; Dai L Magn Reson Chem; 2005 Nov; 43(11):956-61. PubMed ID: 16103990 [TBL] [Abstract][Full Text] [Related]
15. Pharmacology of recombinant hirudin. Nowak G Semin Thromb Hemost; 2002 Oct; 28(5):415-24. PubMed ID: 12420236 [TBL] [Abstract][Full Text] [Related]
16. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Lindhout T; Blezer R; Hemker HC Thromb Haemost; 1990 Nov; 64(3):464-8. PubMed ID: 2096492 [TBL] [Abstract][Full Text] [Related]
17. [Expression and purification of recombinant hirudin]. Guo J; Wang H; Gu J Zhonghua Xue Ye Xue Za Zhi; 1998 Mar; 19(3):146-8. PubMed ID: 11243147 [TBL] [Abstract][Full Text] [Related]